Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy

Gabriel Sperling; Yang Lu; Malek Shatila; Krishnavathana Varatharajalu; Anam Khan; Yinghong Wang; Bryan Schneider

doi:10.1007/978-3-031-83533-9_20

Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy

Gabriel Sperling
, Yang Lu
, Malek Shatila
, Krishnavathana Varatharajalu
, Anam Khan
, Yinghong Wang
, Bryan Schneider

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

This is a patient with anaplastic thyroid cancer who had received two cycles of lenvatinib and pembrolizumab and subsequently developed acute pneumatosis intestinalis and immune-mediated colitis. He was treated with antibiotics, oxygen, and bowel rest with symptomatic remission and resolution on repeat imaging after 7 days. The patient unfortunately expired from cardiac arrest 3 weeks after hospital discharge.

Original language	English (US)
Title of host publication	Challenging Cases in Immunotherapy Related Organ Toxicities
Publisher	Springer Science+Business Media
Pages	143-148
Number of pages	6
ISBN (Electronic)	9783031835339
ISBN (Print)	9783031835322
DOIs	https://doi.org/10.1007/978-3-031-83533-9_20
Publication status	Published - 1 Jan 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Colitis
Immune checkpoint inhibitor
Immunotherapy
Pneumatosis intestinalis

Access to Document

10.1007/978-3-031-83533-9_20

Cite this

@inbook{6ee380a5d5cd462bb16cbabe094e647a,

title = "Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy",

abstract = "This is a patient with anaplastic thyroid cancer who had received two cycles of lenvatinib and pembrolizumab and subsequently developed acute pneumatosis intestinalis and immune-mediated colitis. He was treated with antibiotics, oxygen, and bowel rest with symptomatic remission and resolution on repeat imaging after 7 days. The patient unfortunately expired from cardiac arrest 3 weeks after hospital discharge.",

keywords = "Colitis, Immune checkpoint inhibitor, Immunotherapy, Pneumatosis intestinalis",

author = "Gabriel Sperling and Yang Lu and Malek Shatila and Krishnavathana Varatharajalu and Anam Khan and Yinghong Wang and Bryan Schneider",

note = "Publisher Copyright: {\textcopyright} 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-3-031-83533-9\_20",

language = "English (US)",

isbn = "9783031835322",

pages = "143--148",

booktitle = "Challenging Cases in Immunotherapy Related Organ Toxicities",

publisher = "Springer Science+Business Media",

}

TY - CHAP

T1 - Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy

AU - Sperling, Gabriel

AU - Lu, Yang

AU - Shatila, Malek

AU - Varatharajalu, Krishnavathana

AU - Khan, Anam

AU - Wang, Yinghong

AU - Schneider, Bryan

PY - 2025/1/1

Y1 - 2025/1/1

N2 - This is a patient with anaplastic thyroid cancer who had received two cycles of lenvatinib and pembrolizumab and subsequently developed acute pneumatosis intestinalis and immune-mediated colitis. He was treated with antibiotics, oxygen, and bowel rest with symptomatic remission and resolution on repeat imaging after 7 days. The patient unfortunately expired from cardiac arrest 3 weeks after hospital discharge.

AB - This is a patient with anaplastic thyroid cancer who had received two cycles of lenvatinib and pembrolizumab and subsequently developed acute pneumatosis intestinalis and immune-mediated colitis. He was treated with antibiotics, oxygen, and bowel rest with symptomatic remission and resolution on repeat imaging after 7 days. The patient unfortunately expired from cardiac arrest 3 weeks after hospital discharge.

KW - Colitis

KW - Immune checkpoint inhibitor

KW - Immunotherapy

KW - Pneumatosis intestinalis

UR - https://www.scopus.com/pages/publications/105022220340

U2 - 10.1007/978-3-031-83533-9_20

DO - 10.1007/978-3-031-83533-9_20

M3 - Chapter

AN - SCOPUS:105022220340

SN - 9783031835322

SP - 143

EP - 148

BT - Challenging Cases in Immunotherapy Related Organ Toxicities

PB - Springer Science+Business Media

ER -

Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this